StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.88+0.48 (+34.29%)

Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%

Cadrenal Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Cadrenal Therapeutics's total assets was $5.59M at Jun 30, 2026. For fiscal 2025 it was $4.33M, down 57.3% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.33M-57.3%
FY2024Dec 31, 2024$10.12M+18.8%
FY2023Dec 31, 2023$8.52M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.59M-6.5%
Q1 FY2026Mar 31, 2026$2.86M-64.0%
Q4 FY2025Dec 31, 2025$4.33M-57.3%
Q3 FY2025Sep 30, 2025$4.09M-12.6%
Q2 FY2025Jun 30, 2025$5.98M+9.6%
Q1 FY2025Mar 31, 2025$7.95M+12.8%
Q4 FY2024Dec 31, 2024$10.12M+18.8%
Q3 FY2024Sep 30, 2024$4.68M-49.7%
Q2 FY2024Jun 30, 2024$5.46M+21.8%
Q1 FY2024Mar 31, 2024$7.05M–
Q4 FY2023Dec 31, 2023$8.52M–
Q3 FY2023Sep 30, 2023$9.31M–
Q1 FY2023Mar 31, 2023$4.48M–

More Cadrenal Therapeutics figures

See a number that looks wrong?